Maxwell Skor
Stock Analyst at Morgan Stanley
(4.78)
# 485
Out of 4,478 analysts
212
Total ratings
75.8%
Success rate
27.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maxwell Skor
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| INSM Insmed | Maintained: Buy | $212 | $111.54 | +90.07% | 21 | Jul 6, 2026 | |
| PHVS Pharvaris | Rated: Buy | $41 → $46 | $33.22 | +38.47% | 85 | Jun 25, 2026 | |
| TCRX TScan Therapeutics | Maintained: Hold | n/a | $1.05 | - | 6 | Jun 22, 2026 | |
| CYTK Cytokinetics | Maintained: Buy | $103 | $85.57 | +20.37% | 20 | Jun 16, 2026 | |
| CRNX Crinetics Pharmaceuticals | Maintained: Buy | $87 → $80 | $42.03 | +90.34% | 7 | Jun 15, 2026 | |
| CRSP CRISPR Therapeutics AG | Upgraded: Hold | $60 | $61.89 | -3.05% | 1 | Jun 11, 2026 | |
| ASND Ascendis Pharma | Maintained: Buy | $256 | $267.92 | -4.45% | 22 | May 18, 2026 | |
| BCYC Bicycle Therapeutics | Maintained: Hold | $12 | $4.35 | +175.86% | 8 | May 18, 2026 | |
| MNPR Monopar Therapeutics | Maintained: Buy | $115 | $97.12 | +18.41% | 2 | May 18, 2026 | |
| AVIR Atea Pharmaceuticals | Maintained: Hold | $6 | $4.87 | +23.20% | 9 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $12 | $3.97 | +202.27% | 3 | May 18, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $67 | $33.70 | +98.81% | 11 | May 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Hold | n/a | $3.93 | - | 6 | Aug 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9.5 → $3.55 | $0.834 | n/a | 10 | Nov 20, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $3.25 | $0.6305 | n/a | 1 | Sep 25, 2023 |
Insmed
Jul 6, 2026
Maintained: Buy
Price Target: $212
Current: $111.54
Upside: +90.07%
Pharvaris
Jun 25, 2026
Rated: Buy
Price Target: $41 → $46
Current: $33.22
Upside: +38.47%
TScan Therapeutics
Jun 22, 2026
Maintained: Hold
Price Target: n/a
Current: $1.05
Upside: -
Cytokinetics
Jun 16, 2026
Maintained: Buy
Price Target: $103
Current: $85.57
Upside: +20.37%
Crinetics Pharmaceuticals
Jun 15, 2026
Maintained: Buy
Price Target: $87 → $80
Current: $42.03
Upside: +90.34%
CRISPR Therapeutics AG
Jun 11, 2026
Upgraded: Hold
Price Target: $60
Current: $61.89
Upside: -3.05%
Ascendis Pharma
May 18, 2026
Maintained: Buy
Price Target: $256
Current: $267.92
Upside: -4.45%
Bicycle Therapeutics
May 18, 2026
Maintained: Hold
Price Target: $12
Current: $4.35
Upside: +175.86%
Monopar Therapeutics
May 18, 2026
Maintained: Buy
Price Target: $115
Current: $97.12
Upside: +18.41%
Atea Pharmaceuticals
May 18, 2026
Maintained: Hold
Price Target: $6
Current: $4.87
Upside: +23.20%
May 18, 2026
Maintained: Buy
Price Target: $12
Current: $3.97
Upside: +202.27%
May 6, 2026
Maintained: Buy
Price Target: $67
Current: $33.70
Upside: +98.81%
Aug 22, 2025
Maintained: Hold
Price Target: n/a
Current: $3.93
Upside: -
Nov 20, 2024
Maintained: Buy
Price Target: $9.5 → $3.55
Current: $0.834
Upside: n/a
Sep 25, 2023
Downgraded: Hold
Price Target: $3.25
Current: $0.6305
Upside: n/a